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The shorter life expectancy of patients with type 2 diabetes caused by cardiovascular and cer-
ebrovascular diseases compels clinicians to make a systematic effort to address traditional cardio-
vascular risk factors, such as dyslipidemia, hypertension, hyperglycemia, obesity, and smoking. 
However, another major cardiovascular risk factor substantially influencing the quality and length 
of life – obstructive sleep apnea syndrome (OSA) – is frequently overlooked. OSA is characterized 
by a repetitive upper airway obstruction during sleep leading to intermittent hypoxemia and sleep 
fragmentation. Numerous epidemiological studies have proved that untreated OSA represents an 
independent risk factor significantly increasing all cause as well as cardiovascular, cerebrovascular, 
and cancer mortality (1–7). The importance of OSA is underscored by its considerable prevalence 
ranging from 5 to 10% in the general population and is even higher in the population of type 
2 diabetes patients where a prevalence of ~70% was reported (8–10). Furthermore, ~90% of all 
subjects suffering from moderate or severe OSA remain undiagnosed (11).
Acknowledging the clinical significance of untreated OSA, the American Diabetes Association’s 
Standards of Care recommend the active treatment of OSA when diagnosed (12), while the 
International Diabetes Federation’s guidelines emphasize the need for systematic OSA screening 
in all patients with type 2 diabetes (13). The suggested screening approach is split into two steps. In 
step one, patients fill in a questionnaire stratifying respondents into high or low risk of having OSA. 
Subsequently, in step two, high-risk patients undergo home sleep monitoring consisting of overnight 
registration of pulse oxymetry, preferably combined with nasal flow measurement and other accessory 
signals. Although such a two-step approach seems intuitively attractive, it should be noted that there 
are currently no studies supporting this approach or validating any of the available questionnaires 
in a population of type 2 diabetes patients. In fact, the recommendation suggesting a two-step OSA 
screening procedure is not based on any scientific evidence. Since the performance characteristics of 
screening questionnaires substantially influence the outcome of the whole screening procedure, this 
article scrutinizes the key features of available questionnaires and their performance. Subsequently, 
we will discuss the clinical and ethical impact of OSA questionnaire screening in populations with 
high cardiovascular risk such as patients with type 2 diabetes. The overarching goal of this article is 
to advocate OSA screening in type 2 diabetes patients using simple home sleep monitoring devices 
instead of inaccurate and therefore potentially dangerous questionnaires.
Screening questionnaires were introduced to improve the recognition of patients suffering from 
moderate or severe OSA (indicated for treatment), particularly in primary care practice, where 
such patients remained largely unrecognized without systematic screening. The various question-
naires deployed for screening summarize and quantify the presence of risk factors that are strongly 
associated with OSA – namely, obesity, large neck circumference, hypertension, snoring, and 
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different symptoms of daytime tiredness/sleepiness. However, it 
has proved to be a considerable challenge to create a question-
naire that would be both (1) sensitive enough to minimize the 
chance of marking patients falsely as being at low risk of OSA and 
therefore inadvertently denying them appropriate treatment and 
(2) specific enough to minimize the chance of inappropriately 
marking healthy patients as being at high risk of OSA and leading 
them to the unnecessary use of medical resources.
One of the first questionnaires to be developed and which 
remains widely used is the Berlin questionnaire, an outcome of 
the 1966 Berlin Conference on Sleep in Primary Care. The useful-
ness of the Berlin questionnaire as a tool to recognize patients 
with OSA was consequently validated in a study comparing the 
performance of the Berlin questionnaire with polysomnography 
(which is the gold standard for the diagnosis of OSA). The 
sensitivity and specificity of the Berlin questionnaire to identify 
moderate or severe OSA (i.e., a level of severity where treatment 
is recommended) were found to be 0.54 and 0.97, respectively 
(14). Soon after publication, these results were challenged by 
other clinicians, who recalculated the published data and found 
a sensitivity of 0.95 and specificity of 0.48 (15). Nevertheless, 
the major limitation of the study resides in the fact that the 
high-risk subjects identified by the Berlin questionnaire were 
over-represented in the polysomnography subgroup (69% high-
risk subjects, while there were only 38% high-risk subjects in the 
whole study population). The limited number of low-risk subjects 
as identified by the Berlin questionnaire that were recruited 
into the polysomnography group (31 subjects) also resulted in 
a low number (exactly one patient) of subjects with polysom-
nographically verified severe OSA and nobody with moderate 
OSA. Clearly, the insufficient sample size of the study makes 
sensitivity and specificity calculations unreliable. Consequently, 
several studies retested the performance of the Berlin question-
naire in various countries and in different patient populations 
(primary care patients, preoperative patients, patients referred 
for suspected OSA, or sleep clinic patients), and they reported 
conflicting results with sensitivity and specificity ranging from 
0.43 to 0.89 and 0.33 to 0.79, respectively (16–19). In summary, 
the Berlin questionnaire improves the identification of patients 
with OSA; however, its performance seems to be variable and 
uncertain in studied populations.
In 2006, the STOP and its upgraded version, the STOP Bang 
questionnaires, were introduced and applied in preoperative 
patients (20). Both questionnaires score one point for the pres-
ence of some of the symptoms such as snoring, tiredness, 
observed pauses in breathing, high blood pressure, BMI, age, 
neck circumference, and gender. The initial performance char-
acteristics of the STOP Bang questionnaire validated on 177 
preoperative patients were promising, finding sensitivity 0.92, 
and specificity 0.43 to detect moderate or severe OSA (using a 
total questionnaire scoring of ≥5). With continued recruitment 
and an increased number of assessed subjects to 746, sensitivity 
dropped to 0.23 and specificity increased to 0.56. In an effort to 
increase the questionnaire sensitivity, it was suggested to lower 
the score threshold indicative of being at high risk of having OSA 
to 3 points, which helped to increase sensitivity to 0.68 but at the 
cost of specificity, dropping to 0.11 (21). Furthermore, no study to 
date evaluated the questionnaire separately for men and women 
even though gender plays a major role in the outcome of scoring. 
The key advantage of the STOP and STOP Bang questionnaires 
is their straightforward application and interpretation. However, 
their performance characteristics are too limited to justify their 
use as a screening tool for such a serious condition in a popula-
tion that is already affected by a high incidence of cardiovascular 
events.
A number of other questionnaires were also developed and 
used to screen subjects for OSA, e.g., Epworth’s Sleepiness 
Scale, the ASA Checklist, the Sleep Apnea of Sleep Disorders 
Questionnaire, the Wisconsin Questionnaire, or the Four-
Variable Screening Tool. Although some of them performed 
better than others, none of them was convincing enough to 
become widely adopted in practice. The inherent limitation of 
any OSA screening questionnaire is that some of the answers 
are often based on the patient’s judgment and self-perception. 
For example, when asked about snoring, patients typically rely 
on the information from their bed partners. However, patients 
sleeping in separate bedrooms or living alone might not be able to 
answer appropriately. Similarly, tiredness/sleepiness is frequently 
perceived as a natural symptom of aging or attributed to other 
chronic diseases.
It should be emphasized that a false negative result from an 
OSA screening questionnaire might have serious clinical, ethical, 
and forensic connotations for a type 2 diabetes patient (therefore 
in elevated cardiovascular risk) who is suffering from moderate 
or severe OSA but who is deprived of therapy if inappropriately 
marked as being at low risk. In contrast to questionnaires, 
technological advancements in recent years have opened new 
possibilities for accurate OSA screening in the form of various 
home sleep monitoring devices (typically recording breathing 
and hemoglobin saturation). These devices were shown to have 
an acceptably high sensitivity and specificity ~0.90 (22–24). The 
overall complexity of using home sleep monitoring devices is 
similar to a routinely performed 24-h ECG or a blood pressure 
monitoring device. The growing availability and affordability of 
home sleep monitoring devices raises the fundamental question if 
it is sensible and clinically acceptable to use questionnaires as the 
first screening step. In answer to this, clinicians should examine 
the evidence keeping in mind the best interests of the patient. 
Our analysis found that due to the low sensitivity of question-
naires, questionnaire-based OSA screening fails to identify up 
to 57% of patients with moderate or severe OSA (who should 
receive treatment) while reassuring them that they are at low 
risk of OSA. Support for proceeding directly to OSA screening 
using only home sleep monitoring without prior stratification by 
questionnaire into high- and low-risk groups is strengthened by 
the fact that a substantial number of subjects (in our experience 
about 50% of patients with type 2 diabetes) are identified as high 
risk by questionnaires and anyway subsequently undergo home 
sleep monitoring as a second step in the current two-step OSA 
screening approach.
To conclude, the vast majority of patients with OSA are not 
aware of any illness and they remain undiagnosed. However, OSA 
is an important cardiovascular risk factor highly prevalent in type 
2 diabetes patients. Between 25 and 30% of patients with type 2 
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diabetes who are already at high cardiovascular risk because of 
diabetes also suffer from moderate or severe OSA and should be 
treated as the treatment reduces mortality to the control group 
level. Therefore, physicians should improve the detection of OSA 
ideally via a systematic, precise, and reliable screening program. 
In our view, the recommended optimal OSA screening procedure 
should be evidence-based and reflect technological advancements 
in the field of sleep medicine. Questionnaire-based screening for 
OSA in the type 2 diabetes population is not supported by scien-
tific evidence and might have a consequence as discussed above. 
Therefore, we advocate using home sleep monitoring devices as 
the first and only screening tool in all patients with type 2 diabetes 
as they provide an objective OSA assessment with proven high 
sensitivity and specificity to a level that approaches the gold 
standard polysomnography diagnosis. Moreover, they are easy to 
use by both patients and medical care professionals. Nevertheless, 
screening questionnaires still represent a useful tool for OSA 
screening in the general population where the prevalence of OSA 
is much lower compared to type 2 diabetes population and where 
the clinical consequences of a false negative finding are not so 
detrimental due to the overall lower cardiovascular risk profile.
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